b_leftb_right
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Editorial

Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017

Stephan von Haehling1,*, Nicole Ebner1, Stefan D. Anker2

Version of Record online: 27 OCT 2017

DOI: 10.1002/jcsm.12247


How to Cite

von Haehling, S., Ebner, N., and Anker, S. D. (2017) Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017. Journal of Cachexia, Sarcopenia and Muscle, 8: 675680. doi: 10.1002/jcsm.12247.

Author Information

1
Department of Cardiology and Pneumology, University of Göttingen Medical Center, Göttingen, Germany
2
Division of Cardiology and Metabolism—Heart Failure, Cachexia & Sarcopenia, Department of Cardiology (CVK); and Berlin-Brandenburg Center for Regenerative Therapies (BCRT); Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany

*Correspondence to: Dr Stephan von Haehling, MD PhD FESC, Department of Cardiology and Pneumology, University of Göttingen Medical Center, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany. Tel.: +49 551 39 20911; Fax: +49 551 39 20918. Email: stephan.von.haehling@web.de


The good news first, the Journal of Cachexia, Sarcopenia and Muscle (JCSM) has not only maintained its impact factor, but it has even increased it again, now reaching 9.697 as has been published by Thomson Scientific a few weeks ago. To obtain a grip of the impact factor, it has to be acknowledged that it requires calculation of cites to items published in 2014 and 2015 divided by the number of items published in 2014 and 2015. In numbers, we reached a total of 368 cites in 2014 and 272 cites in 2015, summing up to 640 cites in total. This may not seem a lot, but considering that we only published 66 items deemed countable (editorial comments and letters-to-the-editor are not counted), the final impact factor reached 9.697, implying that each of our papers are cited almost 10 times over the course of 2 years. This places JCSM as the number 8 ranked journal among all journals in the category ‘Medicine, General and Internal’ (Table 1) and as number 2 ranking publication among all nutrition journals, among which, however, JCSM is still not officially listed by Thomson Scientific (Table 2).

As we have done before and are not getting tired of, we herewith express our gratitude to all authors, reviewers, and editorial board members for their great efforts to produce JCSM at good quality, and we greatly appreciate and value also the interest and support of all those who enjoy reading JCSM and cite the papers published there. Of course, the Journal would not be what it is without our editorial office team Monika Diek and Corinna Denecke, and we would also like to express our thanks for their professional support!

Table 1. Top 10 journals in the field ‘medicine: General & Internal’
  ImpactItemsIssues
Journal namefactorpublishedper
  20172015 and 2016Year
1New England Journal of Medicine72.40667052
2Lancet47.83164652
3Journal of the American Medical Association (JAMA)44.40541048
4British Medical Journal20.78544652
5Annals of Internal Medicine17.13515024
6JAMA Internal Medicine16.53827512
7PLOS Medicine11.86228612
8Journal of Cachexia, Sarcopenia and Muscle9.697884
9BMC Medicine7.901418 
10Journal of Internal Medicine7.59819412
Table 2. Top 10 journals in the field ‘Nutrition & Dietetics’, where the Journal of Cachexia, Sarcopenia and Muscle is officially not listed
  ImpactItemsIssues
Journal namefactorpublishedper
  20172015 and 2016Year
1Progress in Lipid Research10.583694
2Annuals Review of Nutrition9.054441
3American Journal of Clinical Nutrition6.92664912
4Critical Reviews in Food Science and Nutrition6.07714912
5International Journal of Obesity5.48750212
6Nutrition Reviews5.29113212
7Advances in Nutrition5.2331776
8Nutrition Research Reviews4.844292
9Clinical Nutrition4.5483756
10Food Chemistry4.529354724

This year is special to JCSM for several reasons. One is the publication of additional issues this year, the other is the inauguration of our two daughter journals. Indeed, JCSM appears to have sparked more scientific interest in the field of body wasting, cachexia, and sarcopenia, and thus the number of submissions to the main journal remains on the increase. With a 73% rejection rate, we are well aware of the fact that we have to decline publication of many good papers, simply for lack of space. However, we do hope that we are able to give some of these a home in our daughter journals—JCSM Rapid Communications and JCSM Clinical Reports. The latter is online already since December 2016, and a good number of original research papers has been published since. At the time of writing this editorial in August 2017, the main journal, JCSM, has received already 187 submissions in 2017 alone, proving a steady increase in submissions: last year, this number was ‘only’ 158. Given these higher numbers of submissions, in 2017 we will move to six issues per year to allow publication of more accepted papers.

We are working hard to provide a timely peer review, which is not always easy, as it is difficult to find appropriate reviewers at times. Articles that are available for the longest time are—not surprisingly—those that have been cited most (Table 3). Our ‘facts and numbers’ editorials remain popular (Tables 4 and 5), and we invite our readers to submit their work or to suggest topics for ‘facts and numbers’ editorials that are relevant to our readers (Table 6).

Table 3. Top 10 of best cited articles since first publication of the Journal of Cachexia, Sarcopenia and Muscle
 First AuthorTitleTypeYearTimes CitedReference
1von HaehlingCachexia as a major underestimated and unmet medical need: facts and numbersEditorial2010203[1]
2von HaehlingAn overview of sarcopenia: facts and numbers on prevalence and clinical impactEditorial2010125[2]
3DaltonThe selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trialOriginal article2011111[3]
4MorleyFrom Sarcopenia to frailty: a road less travelledEditorial201494[4]
5LenkSkeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingReview201090

[5]

6FanzaniMolecular and cellular mechanisms of skeletal muscle atrophy: an updateReview201278[6]
7ElkinaThe role of myostatin in muscle wasting: an overview.Review201175[7]
8CesariBiomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on SarcopeniaOriginal article201272[8]
9MakWasting in chronic kidney diseaseReview201167[9]
10von HaehlingFrom muscle wasting to sarcopenia and myopenia: update 2012Editorial201263[10]
Table 4. Top 20 of best cited articles published 2014 in the Journal of Cachexia, Sarcopenia and Muscle
 First AuthorTitleTypeTimes citedReference
1WakabayashiRehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care managementReview79[11]
2von HaehlingPrevalence, incidence, and clinical impact of cachexia: facts and numbers—update 2014Editorial75[12]
3MorleyPrevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014Editorial69[13]
4MorleyFrom sarcopenia to frailty: a road less travelledEditorial59[4]
5OrmsbeeOsteosarcopenic obesity: the role of bone, muscle, and fat on healthReview39[14]
6HeymsfieldAssessing skeletal muscle mass: historical overview and state of the artReview37[15]
7MorleyAre we closer to having drugs to treat muscle wasting disease?Editorial36[16]
8AnkerMuscle wasting disease: a proposal for a new disease classificationEditorial27[17]
9EbnerHighlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategiesMeeting Report26[18]
10PietraAnamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profileOriginal Article26[19]
11FragalaBiomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adultsOriginal Article25[20]
12PalusMuscle wasting: an overview of recent developments in basic researchReview20[21]
13JosiakSkeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormonesReview20[22]
14ToledoFormoterol in the treatment of experimental cancer cachexia: effects on heart functionOriginal Article19[23]
15AlchinSarcopenia: describing rather than defining a conditionReview17[24]
16ArgilesCachexia: a problem of energetic inefficiencyReview16[25]
17RheeResistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?Editorial15[26]
18KhawajaVentricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signalling in patients with advanced heart failureOriginal Article15[27]
19MirzaAttenuation of muscle wasting in murine C2C12 myotubes by epigallocatechin-3-gallateOriginal Article15[28]
20KirkmanAnabolic exercise in haemodialysis patients: a randomized controlled pilot studyOriginal Article13[29]
Table 5. Top 20 of best cited articles published 2015 in the Journal of Cachexia, Sarcopenia and Muscle
 First AuthorTitleTypeTimes citedReference
1CalvaniBiomarkers for physical frailty and sarcopenia: state of the science and future developmentsReview37[30]
2BowenSkeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise trainingReview36[31]
3EzeokePathophysiology of anorexia in the cancer cachexia syndromeReview28[32]
4FearonRequest for regulatory guidance for cancer cachexia intervention trialsEditorial24[33]
5ChenGhrelin prevents tumour-induced and cisplatin-induced muscle wasting: characterization of multiple mechanisms involvedOriginal Article17[34]
6MangerSkeletal muscle alterations in chronic heart failure: differential effects on quadriceps and diaphragmOriginal Article17[35]
7GrandeExercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic reviewReview16[36]
8SassoA framework for prescription in exercise-oncology researchEditorial14[37]
9Cvan TrobecInfluence of cancer cachexia on drug liver metabolism and renal elimination in ratsOriginal Article13[38]
10DupuySearching for a relevant definition of sarcopenia: results from the cross-sectional EPIDOS studyOriginal Article13[39]
11MorleyRapid screening for sarcopeniaEditorial12[40]
12StephensEvaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patientsOriginal Article11[41]
13FaberImproved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junctionOriginal Article10[42]
14DrescherLoss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatmentReview8[43]
15WakabayashiSkeletal muscle mass is associated with severe dysphagia in cancer patientsOriginal Article8[44]
16DevHypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinicOriginal Article6[45]
17CooperUnderstanding and managing cancer-related weight loss and anorexia: insights from a systematic review of qualitative researchReview6[46]
18MarinoActivin-βC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathwaysOriginal Article6[47]
19HarutaOne-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patientOriginal Article5[48]
20van NorrenBehavioural changes are a major contributing factor in the reduction of sarcopenia in caloric-restricted ageing miceOriginal Article5[49]
Table 6. Top 20 of best cited articles published 2016 in the Journal of Cachexia, Sarcopenia and Muscle
 First AuthorTitleTypeTimes citedReference
1MalmstromSARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomesOriginal Article33[50]
2TyrovolasFactors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent studyOriginal Article12[51]
3Sakumap62/SQSTM1 but not LC3 is accumulated in sarcopenic muscle of miceOriginal Article9[52]
4LoncarCardiac cachexia: hic et nuncReview8[53]
5GoPrognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneOriginal Article6[54]
6de LimaDoxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPK signalling in skeletal muscleOriginal Article6[55]
7LodkaMuscle RING-fingers 2 and 3 maintain striated-muscle structure and functionOriginal Article5[56]
8LewisIncreased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPDOriginal Article5[57]
9Montano-LozaSarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosisOriginal Article4[58]
10Barbosa-SilvaPrevalence of sarcopenia among community-dwelling elderly of a medium-sized South American city: results of the COMO VAI? studyOriginal Article4[59]
11PennaEffect of the specific proteasome inhibitor bortezomib on cancer-related muscle wastingOriginal Article4[60]
12VriesPatient-centred physical therapy is (cost-) effective in increasing physical activity and reducing frailty in older adults with mobility problems: a randomized controlled trial with 6 months follow-upOriginal Article4[61]
13BatistaCachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patientsOriginal Article3[62]
14GironConversion of leucine to β-hydroxy-β-methylbutyrate by α-keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubesOriginal Article3[63]
15LainscakACT-ONE-ACTION at last on cancer cachexia by adapting a novel action beta-blockerEditorial3[64]
16BergerDysfunction of respiratory muscles in critically ill patients on the intensive care unitReview3[65]
17MusolinoMegestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulationOriginal Article3[66]
18NevesWhite adipose tissue cells and the progression of cachexia: inflammatory pathwaysOriginal Article2[67]
19PolgeUBE2B is implicated in myofibrillar protein loss in catabolic C2C12 myotubesOriginal Article2[68]
20PintoImpact of creatine supplementation in combination with resistance training on lean mass in the elderlyOriginal Article2[69]

Finally, we would like to draw attention to the upcoming Cachexia Conference to be held between December 8–10, 2017 in Rome, Italy. The conference became an annual meeting already 2 years ago, and it is a source of stimulating ideas and exchange between clinicians and researchers in the field of cachexia and wasting. Data on the final program and more information is to be found at http://society-scwd.org.

Acknowledgement

The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle. [71]

References

1
von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1–5.
2
von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010;1:129–133.
3
Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011; 2:153–161.
4
Morley JE, von Haehling S, Anker SD, Vellas B. From sarcopenia to frailty: a road less traveled. J Cachexia Sarcopenia Muscle. 2014;5:5–8.
5
Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010;1:9–21.
6
Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an updatee. J Cachexia Sarcopenia Muscle 2012;3:163–179.
7
Elkina Y, von Haehling S, Anker SD, Springer J. The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle 2011;2:143–151.
8
Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, van Kan GA, et al. for the International Working Group on Sarcopenia. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle 2012; 3:181–90.
9
Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in chronic kidney disease. J Cachexia Sarcopenia Muscle 2011;2:9–25.
10
von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle. 2012;3:213–217.
11
Wakabayashi H, Sakuma K. Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. J Cachexia Sarcopenia Muscle 2014;5:269–277.
12
von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014. J Cachexia Sarcopenia Muscle. 2014;5:261–263.
13
Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology—update 2014. J Cachexia Sarcopenia Muscle. 2014;5:253–259.
14
Ormsbee MJ, Prado CM, Ilich JZ, Purcell S, Siervo M, Folsom A, et al. Osteosarcopenic obesity: the role of bone, muscle, and fat on health. J Cachexia Sarcopenia Muscle. 2014;5:183–92.
15
Heymsfield SB, Adamek M, Gonzalez MC, Jia G, Thomas DM. Assessing skeletal muscle mass: historical overview and state of the art. J Cachexia Sarcopenia Muscle. 2014;5:9–18.
16
Morley JE, von Haehling S, Anker SD. Are we closer to having drugs to treat muscle wasting disease? J Cachexia Sarcopenia Muscle. 2014;5:83–87.
17
Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, et al. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle. 2014;5:1–3.
18
Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014;5:27–34.
19
Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014;5:329–37.
20
Fragala MS, Jajtner AR, Beyer KS, Townsend JR, Emerson NS, Scanlon TC, et al. Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults. J Cachexia Sarcopenia Muscle. 2014;5:139–48.
21
Palus S, von Haehling S, Springer J. Muscle wasting: an overview of recent developments in basic research. J Cachexia Sarcopenia Muscle 2014;5:193–198.
22
Josiak K, Jankowska EA, Piepoli MF, Banasiak W, Ponikowski P. Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones. J Cachexia Sarcopenia Muscle. 2014;5:287–296.
23
Toledo M, Springer J, Busquets S, Tschirner A, López-Soriano FJ, Anker SD, et al. Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle 2014;5:315–20.
24
Alchin DR. Sarcopenia: describing rather than defining a condition. J Cachexia Sarcopenia Muscle 2014;5:265–268.
25
Argilés JM, Fontes-Oliveira CC, Toledo M, López-Soriano FJ, Busquets S. Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle 2014;5:279–286.
26
Rhee CM, Kalantar-Zadeh K. Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J Cachexia Sarcopenia Muscle 2014;5:177–180.
27
Khawaja T, Chokshi A, Ji R, Kato TS, Xu K, Zizola C, et al.Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure. J Cachexia Sarcopenia Muscle 2014;5:297–305.
28
Mirza KA, Pereira SL, Edens NK, Tisdale MJ. Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate. J Cachexia Sarcopenia Muscle 2014;5:339–345.
29
Kirkman DL, Mullins P, Junglee NA, Kumwenda M, Jibani MM, Macdonald JH. Anabolic exercise in haemodialysis patients: a randomised controlled pilot study. J Cachexia Sarcopenia Muscle 2014;5:199–207.
30
Calvani R, Marini F, Cesari M, Tosato M, Anker SD, von Haehling S, et al.; SPRINTT consortium. Biomarkers for physical frailty and sarcopenia: state of the science and future developments J Cachexia Sarcopenia Muscle. 2015;6:278–86.
31
Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 2015;6:197–207.
32
Ezeoke CC, Morley JE. Pathophysiology of anorexia in the cancer cachexia syndrome. J Cachexia Sarcopenia Muscle. 2015;6:287–302.
33
Fearon K, Argiles JM, Baracos VE, Bernabei R, Coats A, Crawford J, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle. 2015;6:272–4.
34
Chen JA, Splenser A, Guillory B, Luo J, Mendiratta M, Belinova B, et al. Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. J Cachexia Sarcopenia Muscle. 2015;6:132–43.
35
Henwood TR, Keogh JW, Reid N, Jordan W, Senior HE. Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility. J Cachexia Sarcopenia Muscle. 2014;5:229–236.
36
Grande AJ, Silva V, Maddocks M. Exercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2015;6:208–211.
37
Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015;6:115–124.
38
Cvan Trobec K, Kerec Kos M, Trontelj J, Grabnar I, Tschirner A, Palus S, et al. Influence of cancer cachexia on drug liver metabolism and renal elimination in rats. J Cachexia Sarcopenia Muscle. 2015;6:45–52.
39
Dupuy C, Lauwers-Cances V, Guyonnet S, Gentil C, Abellan Van Kan G, Beauchet O, et al. Searching for a relevant definition of sarcopenia: results from the cross-sectional EPIDOS study. J Cachexia Sarcopenia Muscle. 2015;6:144–54.
40
Morley JE, Cao L. Rapid screening for sarcopenia. J Cachexia Sarcopenia Muscle. 2015;6:312–314.
41
Stephens NA, Skipworth RJ, Gallagher IJ, Greig CA, Guttridge DC, Ross JA, et al. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle. 2015;6:53–61.
42
Faber J, Uitdehaag MJ, Spaander M, van Steenbergen-Langeveld S, Vos P, Berkhout M, et al. Improved body weight and performance status and reduced serum PGE(2) levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. J Cachexia Sarcopenia Muscle. 2015; 6:32–44.
43
Drescher C, Konishi M, Ebner N, Springer J. Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. J Cachexia Sarcopenia Muscle. 2015;6:303–311.
44
Wakabayashi H, Matsushima M, Uwano R, Watanabe N, Oritsu H, Shimizu Y. Skeletal muscle mass is associated with severe dysphagia in cancer patients. J Cachexia Sarcopenia Muscle. 2015;6:351–357.
45
Dev R, Hui D, Chisholm G, Delgado-Guay M, Dalal S, Del Fabbro E, et al. Hypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinic. J Cachexia Sarcopenia Muscle. 2015;6:95–8.
46
Cooper C, Burden ST, Cheng H, Molassiotis A. Understanding and managing cancer-related weight loss and anorexia: insights from a systematic review of qualitative research. J Cachexia Sarcopenia Muscle. 2015;6:99–111.
47
Marino FE, Risbridger G, Gold E. Activin-ßC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. J Cachexia Sarcopenia Muscle. 2015;6:365–380.
48
Haruta I, Fuku Y, Kinoshita K, Yoneda K, Morinaga A, Amitani M, et al. One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient. J Cachexia Sarcopenia Muscle. 2015;6:237–41.
49
van Norren K, Rusli F, van Dijk M, Lute C, Nagel J, Dijk FJ, et al. Behavioural changes are a major contributing factor in the reduction of sarcopenia in caloric-restricted ageing mice. J Cachexia Sarcopenia Muscle. 2015;6:253–68.
50
Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7:28–36.
51
Tyrovolas S, Koyanagi A, Olaya B, Ayuso-Mateos JL, Miret M, Chatterji S, et al. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle. 2016;7:312–21.
52
Sakuma K, Kinoshita M, Ito Y, Aizawa M, Aoi W, Yamaguchi A. p62/SQSTM1 but not LC3 is accumulated in sarcopenic muscle of mice. J Cachexia Sarcopenia Muscle. 2016;7:204–212.
53
Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle. 2016;7:246–260.
54
Go SI, Park MJ, Song HN, Kim HG, Kang MH, Lee HR, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle. 2016;7:567–576.
55
de Lima Junior EA, Yamashita AS, Pimentel GD, De Sousa LG, Santos RV, Gonçalves CL, et al. Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. J Cachexia Sarcopenia Muscle. 2016;7:615–625.
56
Lodka D, Pahuja A, Geers-Knörr C, Scheibe RJ, Nowak M, Hamati J, et al. Muscle RING-finger 2 and 3 maintain striated-muscle structure and function. J Cachexia Sarcopenia Muscle. 2016;7:165–80.
57
Lewis A, Lee JY, Donaldson AV, Natanek SA, Vaidyanathan S, Man WD, et al. Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD. J Cachexia Sarcopenia Muscle. 2016;7:330–44.
58
Montano-Loza AJ, Angulo P, Meza-Junco J, Prado CM, Sawyer MB, Beaumont C, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7:126–35.
59
Barbosa-Silva TG, Bielemann RM, Gonzalez MC, Menezes AM. Prevalence of sarcopenia among community-dwelling elderly of a medium-sized South American city: results of the COMO VAI? study. J Cachexia Sarcopenia Muscle. 2016;7:136–143.
60
Penna F, Bonetto A, Aversa Z, Minero VG, Rossi Fanelli F, Costelli P, et al. Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J Cachexia Sarcopenia Muscle. 2016;7:345–54.
61
de Vries NM, Staal JB, van der Wees PJ, Adang EM, Akkermans R, Olde Rikkert MG, et al. Patient-centred physical therapy is (cost-) effective in increasing physical activity and reducing frailty in older adults with mobility problems: a randomized controlled trial with 6?months follow-up. J Cachexia Sarcopenia Muscle. 2016;7:422–35.
62
Batista ML Jr, Henriques FS, Neves RX, Olivan MR, Matos-Neto EM, Alcântara PS, et al. Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients. J Cachexia Sarcopenia Muscle. 2016;7:37–47.
63
Girón MD, Vílchez JD, Salto R, Manzano M, Sevillano N, Campos N, et al. Conversion of leucine to ß-hydroxy-ß-methylbutyrate by a-keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes. J Cachexia Sarcopenia Muscle. 2016;7:68–78.
64
Lainscak M, Laviano A. ACT-ONE-ACTION at last on cancer cachexia by adapting a novel action beta-blocker. J Cachexia Sarcopenia Muscle. 2016;7:400–402.
65
Berger D, Bloechlinger S, von Haehling S, Doehner W, Takala J, Z'Graggen WJ, et al. Dysfunction of respiratory muscles in critically ill patients on the intensive care unit. J Cachexia Sarcopenia Muscle. 2016;7:403–12.
66
Musolino V, Palus S, Tschirner A, Drescher C, Gliozzi M, Carresi C, et al. Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation. J Cachexia Sarcopenia Muscle. 2016;7:555–566.
67
Neves RX, Rosa-Neto JC, Yamashita AS, Matos-Neto EM, Riccardi DM, Lira FS, et al. White adipose tissue cells and the progression of cachexia: inflammatory pathways. J Cachexia Sarcopenia Muscle 2016;7:193–203.
68
Polge C, Leulmi R, Jarzaguet M, Claustre A, Combaret L, Béchet D, et al. UBE2B is implicated in myofibrillar protein loss in catabolic C2C12 myotubes. J Cachexia Sarcopenia Muscle. 2016;7:377–87.
69
Pinto CL, Botelho PB, Carneiro JA, Mota JF. Impact of creatine supplementation in combination with resistance training on lean mass in the elderly. J Cachexia Sarcopenia Muscle. 2016;7:413–421.
70
www.webofknowledge.com (accessed 08/08/2017).
71
von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle 2015;4:315–316.